← Evidence map

ArticleOphthalmology and therapy2026

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US.

Andreas Kuznik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. | OpenQuestion